Neoadjuvant Treatment for Locally Invasive Esophageal Cancer

Wade T. Iams, Victoria Meucci Villaflor*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Locally advanced esophageal carcinoma has a poor prognosis, and epidemiologic trends show that more patients are being diagnosed with locally advanced esophageal carcinoma and with adenocarcinoma histology. This prompts a review and evaluation of the field regarding standard of care treatment for patients with locally advanced esophageal carcinoma, both adenocarcinoma and squamous cell carcinoma. We review the evidence showing the moderate benefit of neoadjuvant chemoradiation followed by esophagectomy compared to perioperative chemotherapy plus esophagectomy in patients who are good operative candidates. Also, we summarize the emerging clinical trial landscape in the perioperative setting primarily seeking to apply targeted therapies against HER2 (trastuzumab or pertuzumab) or immune checkpoint inhibitors against programmed death 1 (PD-1; pembrolizumab and nivolumab) or programmed death ligand 1 (PD-L1; durvalumab). Understanding the foundations that have determined the current standard of care for patients with locally advanced esophageal carcinoma will aid in interpreting the clinical trial results that will soon appear with the novel treatment strategies.

Original languageEnglish (US)
Pages (from-to)1719-1725
Number of pages7
JournalWorld Journal of Surgery
Issue number7
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Neoadjuvant Treatment for Locally Invasive Esophageal Cancer'. Together they form a unique fingerprint.

Cite this